Trial Profile
Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb) in Patients With ErbB2-Positive Stage I-III Breast Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 14 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 23 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.